AKT activation, due to receptor tyrosine kinase transactivation, was shown to inhibit the FAS-associated factor 1 (FAF1)-mediated destabilization of the TGFβ receptor 2 (TβRII) in breast cancer cells. The gene discussed is AKT1; the disease is breast cancer.